TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Prostatype Genomics AB
Closing information (x1000 NOK)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 |
| Turnover |
205
|
1,374
|
646 |
| Financial expenses |
1,729
|
2,221
|
375 |
| Earnings before taxes |
-42,336
|
-41,975
|
-27,514 |
| EBITDA |
-40,091
|
-37,859
|
-25,337 |
| Total assets |
43,284
|
49,863
|
29,276 |
| Current assets |
12,195
|
26,248
|
13,403 |
| Current liabilities |
8,767
|
24,801
|
4,098 |
| Equity capital |
34,516
|
24,995
|
24,737 |
| - share capital |
691
|
7,261
|
1,298 |
| Employees (average) |
6
|
7
|
6 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 |
| Solvency |
79.7%
|
50.1%
|
84.5% |
| Turnover per employee |
34
|
196
|
108 |
| Profit as a percentage of turnover |
-20651.7%
|
-3054.9%
|
-4259.1% |
| Return on assets (ROA) |
-93.8%
|
-79.7%
|
-92.7% |
| Current ratio |
139.1%
|
105.8%
|
327.1% |
| Return on equity (ROE) |
-122.7%
|
-167.9%
|
-111.2% |
| Change turnover |
-1,193
|
682
|
637 |
| Change turnover % | -85% | 6730% | |
| Chg. No. of employees |
-1
|
1
|
1 |
| Chg. No. of employees % | -14% | 20% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.